Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00413647 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease

A Phase 1 study of Coronary Artery Disease, sponsored by Fluoropharma.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target
1
Study location

NCT00413647: Completed Phase 1 study of Coronary Artery Disease, sponsored by Fluoropharma.

NCT00413647 is a Phase 1 study of Coronary Artery Disease that has completed, run by Fluoropharma. The registered enrollment target is 21 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00413647, a Phase 1 study of Coronary Artery Disease, has completed, sponsored by Fluoropharma.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD subjects both male and female between the ages of 50-85. Nine normal controls will undergo repeated whole body imaging for biodistribution and dosimetry estimation. Six other normal healthy subjects will undergo heart imaging only. Six CAD subjects will undergo heart imaging only.

Primary Outcome

Normal healthy volunteers for whole body imaging group and NHV and Coronary Artery Disease (CAD)undergoing cardiac imaging.

Conditions Studied

Interventions

  • DRUG CardioPET

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2006-09
Est. Completion 2008-02
Phase Phase 1
Fluoropharma

2 total trials

What the finished NCT00413647 record still lists

NCT00413647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which CardioPET is the first listed.

NCT00413647 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00413647 about?

NCT00413647 is a clinical study titled "A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease". Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD subjects both male and female between the ages of 50-85. Nine normal controls will undergo repeated whole body imaging for biodistribution and dosimetry estimation. Six other normal healthy subjects will underg...

What is the current status of trial NCT00413647?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2006-09. Estimated completion is 2008-02.

What conditions does trial NCT00413647 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT00413647?

The interventions under investigation include: CardioPET (DRUG).

Who is sponsoring clinical trial NCT00413647?

This trial is sponsored by Fluoropharma, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00413647 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00413647's enrollment target sits among peer trials

21 207th of 219 higher than 12 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00413647, the US trial registry maintained by the National Library of Medicine. NCT00413647 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.